Advanced Enzyme Technologies will acquire a 70 per cent stake in JC Biotech, a city-based Active Pharma Ingredients (APIs) maker, for Rs 50 crore.
Advanced Enzyme, a leading speciality biotech company that manufactures enzymes, today said it has entered into definitive agreements with JC Biotech for the stake buy.
The company, in a statement said, the proposed transaction was approved by its board today.
C L Rathi, Managing Director, Advanced Enzymes, said "we expect this deal to immediately strengthen our market leadership in API Serratiopeptidase, giving us significant competitive advantage as well as flexibility in production.
"JC Biotech has the ability to handle solvent-based fermentation & recovery, which is highly complementary to our current production process."
JC Biotech is the maker of API Serratiopeptidase, an anti-inflammatory enzyme, and has a research and development pipeline of biopharma molecules.
It also has a fairly advanced technology for the manufacturing of algal DHA, an Omega 3 Fatty Acid which finds great application in Human Nutrition, the statement said.
As on March 31, 2016, JC Biotech's revenues stood at Rs 39 crores with a profit after tax (PAT) of Rs 2.5 crore.
The acquisition is expected to close latest by the end of December. Advanced Enzymes will finance the acquisition largely through internal accruals, the statement added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
